Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 110

1.

A randomized, multi-center, open-label, phase II study of once-per-cycle DA-3031, a biosimilar pegylated G-CSF, compared with daily filgrastim in patients receiving TAC chemotherapy for early-stage breast cancer.

Park KH, Sohn JH, Lee S, Park JH, Kang SY, Kim HY, Park IH, Park YH, Im YH, Lee HJ, Hong DS, Park S, Shin SH, Kwon HC, Seo JH.

Invest New Drugs. 2013 Oct;31(5):1300-6. doi: 10.1007/s10637-013-9973-4. Epub 2013 May 16.

PMID:
23677653
[PubMed - indexed for MEDLINE]
2.

A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy.

Green MD, Koelbl H, Baselga J, Galid A, Guillem V, Gascon P, Siena S, Lalisang RI, Samonigg H, Clemens MR, Zani V, Liang BC, Renwick J, Piccart MJ; International Pegfilgrastim 749 Study Group.

Ann Oncol. 2003 Jan;14(1):29-35.

PMID:
12488289
[PubMed - indexed for MEDLINE]
Free Article
3.

Comparable efficacy and safety profiles of once-per-cycle pegfilgrastim and daily injection filgrastim in chemotherapy-induced neutropenia: a multicenter dose-finding study in women with breast cancer.

Holmes FA, Jones SE, O'Shaughnessy J, Vukelja S, George T, Savin M, Richards D, Glaspy J, Meza L, Cohen G, Dhami M, Budman DR, Hackett J, Brassard M, Yang BB, Liang BC.

Ann Oncol. 2002 Jun;13(6):903-9.

PMID:
12123336
[PubMed - indexed for MEDLINE]
Free Article
4.

Pegylated filgrastim is comparable with filgrastim as support for commonly used chemotherapy regimens: a multicenter, randomized, crossover phase 3 study.

Shi YK, Chen Q, Zhu YZ, He XH, Wang HQ, Jiang ZF, Chang JH, Liu YP, Wang AL, Luo DY, Zhang Y, Ke XY, Li WL, Zhang WJ, Wang XW, Zhang YP, Wang JM, Liu XQ.

Anticancer Drugs. 2013 Jul;24(6):641-7. doi: 10.1097/CAD.0b013e3283610b5d.

PMID:
23571496
[PubMed - indexed for MEDLINE]
5.

Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer.

Holmes FA, O'Shaughnessy JA, Vukelja S, Jones SE, Shogan J, Savin M, Glaspy J, Moore M, Meza L, Wiznitzer I, Neumann TA, Hill LR, Liang BC.

J Clin Oncol. 2002 Feb 1;20(3):727-31.

PMID:
11821454
[PubMed - indexed for MEDLINE]
6.

Phase III trial comparing granulocyte colony-stimulating factor to leridistim in the prevention of neutropenic complications in breast cancer patients treated with docetaxel/doxorubicin/cyclophosphamide: results of the BCIRG 004 trial.

Nabholtz JM, Cantin J, Chang J, Guevin R, Patel R, Tkaczuk K, Vodvarka P, Lindsay MA, Reese D, Riva A, Mackey J.

Clin Breast Cancer. 2002 Oct;3(4):268-75.

PMID:
12425755
[PubMed - indexed for MEDLINE]
7.

The efficacy and safety of FSK0808, filgrastim biosimilar: a multicenter, non-randomized study in Japanese patients with breast cancer.

Sagara Y, Sato K, Fukuma E, Higaki K, Mizutani M, Osaki A, Takano T, Tokuda Y, Ohno S, Masuda N, Suzuki M, Saeki T.

Jpn J Clin Oncol. 2013 Sep;43(9):865-73. doi: 10.1093/jjco/hyt091. Epub 2013 Jul 14.

PMID:
23858037
[PubMed - indexed for MEDLINE]
Free Article
8.

Bone pain associated with once-per-cycle pegfilgrastim is similar to daily filgrastim in patients with breast cancer.

Kubista E, Glaspy J, Holmes FA, Green MD, Hackett J, Neumann T; Pegfilgrastim Study Group.

Clin Breast Cancer. 2003 Feb;3(6):391-8.

PMID:
12636878
[PubMed - indexed for MEDLINE]
9.

Low-dose filgrastim in patients with breast cancer treated with docetaxel, doxorubicin, and cyclophosphamide.

Ip EJ, Lee-Ma A, Troxell LS, Chan J.

Am J Health Syst Pharm. 2008 Aug 15;65(16):1552-5. doi: 10.2146/ajhp070489.

PMID:
18693211
[PubMed - indexed for MEDLINE]
10.

Pegfilgrastim +/- ciprofloxacin for primary prophylaxis with TAC (docetaxel/doxorubicin/cyclophosphamide) chemotherapy for breast cancer. Results from the GEPARTRIO study.

von Minckwitz G, Kümmel S, du Bois A, Eiermann W, Eidtmann H, Gerber B, Hilfrich J, Huober J, Costa SD, Jackisch C, Grasshoff ST, Vescia S, Skacel T, Loibl S, Mehta KM, Kaufmann M; German Breast Group.

Ann Oncol. 2008 Feb;19(2):292-8. Epub 2007 Sep 9.

PMID:
17846019
[PubMed - indexed for MEDLINE]
Free Article
11.

XM02, the first biosimilar G-CSF, is safe and effective in reducing the duration of severe neutropenia and incidence of febrile neutropenia in patients with small cell or non-small cell lung cancer receiving platinum-based chemotherapy.

Gatzemeier U, Ciuleanu T, Dediu M, Ganea-Motan E, Lubenau H, Del Giglio A.

J Thorac Oncol. 2009 Jun;4(6):736-40. doi: 10.1097/JTO.0b013e3181a52964.

PMID:
19404210
[PubMed - indexed for MEDLINE]
12.

Frequency of febrile neutropenia in breast cancer patients receiving epirubicin and docetaxel/paclitaxel with colony-stimulating growth factors: a comparison of filgrastim or lenograstim with pegfilgrastim.

Schippinger W, Holub R, Dandachi N, Bauernhofer T, Samonigg H.

Oncology. 2006;70(4):290-3. Epub 2006 Aug 4.

PMID:
16899982
[PubMed - indexed for MEDLINE]
13.

Filgrastim-mediated neutrophil recovery in patients with breast cancer treated with docetaxel and doxorubicin.

Meza LA, Green MD, Hackett JR, Neumann TA, Holmes FA.

Pharmacotherapy. 2003 Nov;23(11):1424-31.

PMID:
14620389
[PubMed - indexed for MEDLINE]
14.

An open-label multicenter safety, tolerability, and efficacy study of recombinant granulocyte colony-stimulating factor in the prevention of neutropenic complications in breast cancer patients.

Sveikata A, Liutkauskienė S, Juozaitytė E, Characiejus D, Tamošaitytė L, Šeštakauskas K.

Medicina (Kaunas). 2011;47(8):428-33. Epub 2011 Nov 18.

PMID:
22123557
[PubMed - indexed for MEDLINE]
Free Article
15.

[Treatment of chemotherapy-induced neutropenia pegylated recombinant human granulocyte colony-stimulating factor: a multi-center randomized controlled phase II clinical study].

Shi YK, He XH, Yang S, Wang HQ, Jiang ZF, Zhu YZ, Ke XY, Zhang Y, Liu YP, Zhang WJ, Wang Z, Shi QZ, Xie XD, Zhang HL, Wang JJ, Luo DY, Zheng QS, Sun RY.

Zhonghua Yi Xue Za Zhi. 2006 Dec 26;86(48):3414-9. Chinese.

PMID:
17313855
[PubMed - indexed for MEDLINE]
16.

Retrospective comparison of neutropenia in children with Ewing sarcoma treated with chemotherapy and granulocyte colony-stimulating factor (G-CSF) or pegylated G-CSF.

Milano-Bausset E, Gaudart J, Rome A, Coze C, Gentet JC, Padovani L, Lacarelle B, André N.

Clin Ther. 2009;31 Pt 2:2388-95. doi: 10.1016/j.clinthera.2009.11.013.

PMID:
20110048
[PubMed - indexed for MEDLINE]
17.
18.

Pegfilgrastim and daily granulocyte colony-stimulating factor: patterns of use and neutropenia-related outcomes in cancer patients in Spain--results of the LEARN Study.

Almenar D, Mayans J, Juan O, Bueno JM, Lopez JI, Frau A, Guinot M, Cerezuela P, Buscalla EG, Gasquet JA, Sanchez J.

Eur J Cancer Care (Engl). 2009 May;18(3):280-6. doi: 10.1111/j.1365-2354.2008.00959.x. Epub 2008 Dec 8.

PMID:
19076208
[PubMed - indexed for MEDLINE]
Free PMC Article
19.

The role of granulocyte colony-stimulating factor (filgrastim) in maintaining dose intensity during conventional-dose chemotherapy with ABVD in Hodgkin's disease.

Silvestri F, Fanin R, Velisig M, Barillari G, Virgolini L, Zaja F, Russo D, Baccarani M.

Tumori. 1994 Dec 31;80(6):453-8.

PMID:
7534963
[PubMed - indexed for MEDLINE]
20.

Toxicity and health-related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC): impact of adding primary prophylactic granulocyte-colony stimulating factor to the TAC regimen.

Martín M, Lluch A, Seguí MA, Ruiz A, Ramos M, Adrover E, Rodríguez-Lescure A, Grosse R, Calvo L, Fernandez-Chacón C, Roset M, Antón A, Isla D, del Prado PM, Iglesias L, Zaluski J, Arcusa A, López-Vega JM, Muñoz M, Mel JR.

Ann Oncol. 2006 Aug;17(8):1205-12. Epub 2006 Jun 9.

PMID:
16766587
[PubMed - indexed for MEDLINE]
Free Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk